Neuropsychiatric Manifestations and Cognitive Decline in Patients With Long-Standing Lyme Disease: A Scoping Review

Marissa Brackett1, Jacklyn Potts1, Allison Meihofer1

  • 1Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, USA.

Cureus
|May 16, 2024
PubMed

Insights

Long-standing Lyme disease (LD) can cause chronic neuropsychiatric and cognitive issues. Delayed diagnosis of Lyme disease often worsens these persistent symptoms, highlighting the need for greater awareness.

Area of Science:

  • Neuroscience
  • Infectious Diseases
  • Public Health

Background:

  • Lyme disease (LD), caused by *Borrelia burgdorferi*, is a tick-borne illness.
  • Chronic symptoms, including neuropsychiatric and cognitive issues, can persist post-treatment.
  • Long-standing LD (LSLD) presents significant challenges in diagnosis and management.

Purpose of the Study:

  • To review neuropsychiatric manifestations and cognitive decline in LSLD patients.
  • To examine the impact of delayed diagnosis on symptom severity in LSLD.
  • To highlight LSLD as an often-overlooked diagnosis.

Main Methods:

  • A scoping review was conducted.
  • Searched Embase, MEDLINE, and Web of Science databases.
  • Included 10 articles reporting on LSLD, neuropsychiatric/cognitive symptoms, and delayed diagnosis.

Main Results:

  • Neuropsychiatric symptoms included depression, anxiety, anger, and suicidal ideation.
  • Cognitive deficits involved memory, attention, and executive functions.
  • Delayed LD diagnosis correlated with increased symptom severity.

Conclusions:

  • Neuropsychiatric and cognitive symptoms are common in chronic Lyme disease.
  • Delayed diagnosis exacerbates symptom severity in LSLD.
  • Further research is needed to understand the relationship between diagnosis time and symptom severity in LSLD.

Related Concept Videos

Long-term Depression01:03

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
2.5K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
467
Long-term Potentiation01:35

Long-term Potentiation

Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
55.1K
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
48
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
120
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
181